Stock Analiz

Mereo BioPharma Group plc MREO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.31Market cap $49M
Open the interactive analysis →

Mereo BioPharma Group plc (MREO) is a healthcare company listed in the US with a market value of about $49M. In fiscal year 2025 it had revenue of $500000 and net income of -$42M, a net margin of -8375.6%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -65%.

About Mereo BioPharma Group

Mereo BioPharma Group is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $49M in 2021 to $500000 in 2025, a decline of about 68.2% a year. It was profitable in 1 of the last 10 years in our data. It spends 3553% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S98.2
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-63.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2878.5%
ROIC (5-yr avg.)-64.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$500000$0$10M$0$49M—————
Net income-$42M-$43M-$29M-$42M$17M-$223M-$46M-$41M-$52M-$35M
Free cash flow-$31M-$33M-$21M-$49M-$8M-$39M-$61M-$30M-$43M-$37M
EPS (diluted)$-0.26$-0.27$-0.18$-0.26$0.11$-1.40$-0.29$-0.26$-0.33$-0.22
Net margin-8375.6%—-294.7%—34.9%—————
ROIC-97.5%-70.3%-53.6%-80.1%-22.6%-3153.9%-55.1%-54.6%-45.0%-38.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Mereo BioPharma Group pay a dividend?

Not currently.

Is Mereo BioPharma Group a good stock to buy?

We do not give buy or sell advice. Mereo BioPharma Group scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.